MedTrace Logo

Implementation of SGLT-2 Inhibitors in Patients With Heart Failure Through a New Digital Strategy

NCT05890131 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5996

Last updated 2026-04-13

No results posted yet for this study

Summary

The implementation of new medical therapies and guidelines, is a long and complex process that takes up to 10 years on average. This prolonged process is a global challenge and is mainly due to the complexity of cross-institutional patient care, involving primary care, out-patient clinics, nursing homes and patient associations.

The main objective of this clinical trial is to determine whether a new digital strategy that employs official digital letters to inform and invite patients to evaluate their eligibility for new therapies, specifically the sodium-glucose co-transporter-2 (SGLT-2) inhibitor for heart failure patients, can facilitate and optimise the implementation. The aim is to increase the number of eligible patients with heart failure who start taking SGLT-2 inhibitors and reduce the time it takes to initiate treatment compared to the current process. Ultimately, this approach may improve patient outcomes.

Conditions

Interventions

OTHER

Digital letter

A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.

Sponsors & Collaborators

  • Morten Schou

    lead OTHER

Principal Investigators

  • Morten Schou, MD, PhD · Department of Cardiology, Herlev and Gentofte Hospital, 2900 Hellerup, Denmark

  • Lars Køber, MD, DMSc · Department of Cardiology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-03
Primary Completion
2026-04-07
Completion
2026-04-07

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05890131 on ClinicalTrials.gov